BMY vs ROIV
BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally. ROIV: Roivant Sciences is a biopharma company that accelerates drug development through a decentralized model of nimble, independent 'Vant' subsidiaries and proprietary computational tools.
Side-by-side fundamentals
| Metric | BMY | ROIV | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $64.72 | $36.34 | |
| Market cap as of 2026-08-09 | $132.2B | $26.2B | |
| P/E as of 2026-08-09 | 14.24 | n/a | |
| PEG as of 2026-08-09 | -8.67 | n/a | |
| Net margin as of 2026-08-09 | +18.9% | -3629.2% | BMY higher |
| Gross margin as of 2026-08-09 | +71.7% | +84.4% | ROIV higher |
| Operating margin as of 2026-08-09 | +25.5% | -6102.2% | BMY higher |
| ROE as of 2026-08-09 | +46.8% | -6.9% | BMY higher |
| ROA as of 2026-08-09 | +10.3% | -5.7% | BMY higher |
| Debt / equity as of 2026-08-09 | 1.93 | 0.00 | ROIV lower |
| Revenue growth (YoY) as of 2026-08-09 | +3.1% | -89.2% | BMY higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | -36.0% | BMY higher |
| Dividend yield as of 2026-08-09 | +3.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-09 | 0.17 | 1.11 | |
| 1-year return as of 2026-08-07 close | +42.7% | +214.6% | ROIV higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.